Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 17,846 matching trials from the live ClinicalTrials.gov search.
Conditions
Thalassemia Major
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
0 Years to 30 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
51
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
Conditions
Atrial Fibrillation
Interventions
RSD1235
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Huntsville, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System

NCT07498322
Conditions
Opiod Use Disorder
Interventions
OUD screening, MOUD, Continuity of care
Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
16 Years and older
Enrollment
271,031 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Major Depressive Disorder
Interventions
SEP-363856, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
53
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Conditions
Clostridium Difficile Infection
Interventions
Cadazolid, Vancomycin, Placebo-matching cadazolid, Placebo-matching vancomycin
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Newark, Delaware • Jacksonville, Florida • Orlando, Florida + 8 more
Conditions
Prostate Cancer
Interventions
Radiation, Androgen Suppression Therapy
Radiation · Drug
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
4
States / cities
Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more
Conditions
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
96
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more
Conditions
Breast Cancer
Interventions
Mifepristone, Placebo, Nab-Paclitaxel
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Evanston, Illinois + 2 more
Conditions
Depression
Interventions
citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine)
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Trial of the TELL Tool Intervention

NCT04841967
Conditions
Fertility Issues, Disclosure, Parenting
Interventions
TELL Tool Intervention, eBook Attention Control
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Tourette Syndrome
Interventions
SNC-102 sustained release tablet
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Manhasset, New York
Conditions
Multiple Myeloma
Interventions
GSK2110183, Bortezomib, Dexamethasone
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 5 more
Completed Phase 3 Interventional Results available

Natalizumab Re-Initiation of Dosing

NCT00306592
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BG00002 (natalizumab)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Telavancin in Normal and Obese Subjects

NCT02753855
Conditions
Healthy
Interventions
Telavancin
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
Conditions
Peanut Allergy
Interventions
Peanut SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
4 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Conditions
Solid Tumor, Pancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions
PAC-1
Drug
Lead sponsor
Vanquish Oncology, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Saint Paul, Minnesota
Conditions
Heart Failure, Congestive
Interventions
Levosimendan
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
132
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Active, not recruiting Not applicable Interventional

Uptake of Genetic Counseling Among African American Women

NCT04082117
Conditions
Breast Cancer Risk
Interventions
Educational video
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
25 Years to 69 Years · Female only
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Chicago, Illinois
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Screening for High Frequency Malignant Disease

NCT05117840
Conditions
Lung Cancer
Interventions
Low-dose CT scan
Device
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
12,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
125
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Anaheim, California + 105 more
Conditions
Bronchiectasis
Interventions
Itepekimab (SAR440340), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Westminster, California + 20 more